Practical, structured cancer guides for patients and families โ step-by-step help on diagnosis, treatment decisions, second opinions, clinical trials, and international cancer care.
Walk-throughs for the moments that matter โ from reading a biopsy report to preparing for treatment abroad.
Every patient's cancer journey involves dozens of decisions โ what report says what, which specialist to consult, whether to seek a second opinion, what to ask before travelling abroad, how to compare treatment plans, and when to consider advanced therapies or clinical trials.
CancerFax Guides are structured walk-throughs designed to make these decisions clearer. Each guide breaks a specific situation into practical steps, expected questions, and what to watch for โ so families can move forward calmly, with proper preparation, and with better conversations with their oncology teams.
international-cancer-treatment
No single country leads in every cancer type. The USA leads in targeted therapy access, Germany in tumor board culture, Israel in precision oncology, South Korea in gastric cancer outcomes, India in cost, and Japan in carbon ion therapy.
Eight curated paths through the CancerFax library โ organised the way patients actually think about cancer decisions.
Read biopsy reports, pathology, scan findings, and staging results โ and understand what each line on the report actually means for treatment.
Compare treatment options, evaluate trade-offs, and understand what questions to ask before agreeing to a specific protocol.
Prepare records, frame the right clinical questions, and compare opinions โ local and international โ without feeling rushed.
How trial matching works, eligibility logic explained, document checklists, and what to expect during screening for international trials.
Step-by-step preparation for CAR-T, TIL, gene therapy, proton therapy, BNCT, HIFU, and other advanced options where eligibility matters.
How to choose a cancer centre, evaluate a specialist team, assess clinical trial access, and avoid common selection mistakes.
Step-by-step preparation for cross-border cancer treatment โ China and India access pathways, visas, costs, accommodation, and follow-up planning.
Practical walk-throughs for the families, partners, and adult children walking alongside someone in cancer treatment โ what to organise, what to ask.
Recently published step-by-step guides on cancer treatment, clinical trials, advanced therapies, and global oncology decision-making.
CAR-T Cell Therapy
CAR-T for leukemia: Kymriah approved for B-ALL (CR 70-90%), Breyanzi for adult B-ALL (CR 63%), liso-cel for CLL (ORR 43%). AML CAR-T is in trials. Chinese academic centres run the most active AML CAR-T programmes globally targeting CD33, CD123, and CLL-1.
Read guideInternational Cancer Treatment
China treats more cancer patients than any other country, with globally leading expertise in liver, esophageal, gastric, and nasopharyngeal cancers. Top-tier university hospitals in Beijing and Shanghai offer internationally benchmarked oncology, particle therapy at competitive pricing, and growing clinical trial access.
Read guideguide
Prepared by the CancerFax oncology navigation team. Updated regularly based on treatment access and clinical practice.
Read guideBrain Tumours
Primary CNS lymphoma (PCNSL) is an aggressive diffuse large B-cell lymphoma confined to the brain, spine, vitreous, or CSF. High-dose methotrexate-based induction followed by consolidation is the international standard โ with ibrutinib and rituximab-containing combinations showing significant activity in relapsed and refractory disease.
Read guideHead and Neck Oncology
China is a global leader in head and neck cancer treatment โ particularly for nasopharyngeal carcinoma (NPC), where Chinese academic centres have the world's highest caseload and the most developed evidence base. Advanced modalities including intensity-modulated proton therapy, BNCT, and immunotherapy combinations are accessible at major Chinese oncology centres, often at 60โ75% lower cost than in Western countries.
Read guideBrain Tumours
China offers some of Asia's highest-volume brain tumour expertise โ Beijing Tiantan Hospital is the world's largest neurosurgery centre by volume, and SPHIC Shanghai is one of only ~15 facilities globally offering carbon ion therapy. International patients access both via CancerFax with full logistics coordination.
Read guideThe right guide depends on where you are standing right now. Pick the stage that fits.
Understand your diagnosis, staging, reports, and first-line treatment options before making major decisions.
Read newly-diagnosed guidesExplore second opinions, molecular testing, clinical trials, advanced therapies, and international options.
Explore next-step guidesLearn how trial matching, eligibility review, mutation testing, and hospital screening actually work.
View clinical trial guidesUnderstand how destination, treatment availability, cost, language, expertise, and logistics shape decisions.
Compare destinationsReset the picture with biomarker re-testing, trial review, and structured advanced-therapy assessment.
Read relapse guidesWhat records to organise, what to ask, and how to compare opinions without rushing into a decision.
Plan a second opinionPractical guides for the families, partners, and adult children walking alongside someone in cancer treatment.
Read caregiver guidesSurveillance scans, recurrence risk, MRD testing, lifestyle, and continued follow-up across borders.
Explore follow-up guidesPreparation walk-throughs for emerging and advanced treatment options โ cell therapy, gene therapy, immunotherapy, precision radiation, and investigational treatments.
Cell & gene therapy
Precision oncology
Advanced radiation & local therapies
The therapies and procedures patients ask us about most.
Each link opens the full CancerFax condition page with treatment pathways, advanced options, hospitals, and relevant patient stories.
Understanding access
Clinical trials may offer access to promising treatment options when standard therapies have limited benefit. CancerFax Guides walk patients through how trials work, who may be eligible, what documents are required, and what questions should be asked before considering trial participation.
2,400+
Active oncology trials reviewed across our partner network in 2025
18 countries
Where CancerFax has supported document preparation, hospital coordination, or trial screening
Honest first.
We never present an investigational therapy as guaranteed standard-of-care.
Walk-throughs chosen by the CancerFax editorial team โ especially for patients dealing with complex, advanced, relapsed, or treatment-resistant cancers.
Cancer Treatment in India ยท 10 min
02Yttrium-90 Therapy ยท 22 min
03international-cancer-treatment ยท 9 min
04guide ยท 7 min
05MCTL Therapy ยท 9 min
06International Cancer Treatment ยท 10 min
The CancerFax perspective
At CancerFax, we believe cancer guidance must be honest, compassionate, and medically responsible. Patients should not be pushed toward any hospital, country, or treatment without proper evaluation.
Our guides are designed to help families understand possibilities, limitations, risks, costs, and eligibility before making treatment decisions. We focus especially on advanced cancer treatment access, international second opinions, clinical trial preparation, and complex oncology navigation for patients who need more than routine medical tourism support.
โ The CancerFax Editorial & Clinical Team
Direct answers to the questions readers ask most often.
Whether you need to read a report, prepare a second opinion, explore clinical trials, or understand an advanced therapy โ CancerFax guides are here to help you move forward with clarity.
CancerFax guides are for patient education and decision support only. Always consult a qualified oncologist before making treatment decisions.
Medical Disclaimer:CancerFax Guides are educational resources intended to support patient understanding and informed decision-making. They are not medical advice and should not replace consultation with a qualified oncologist or medical professional. Treatment decisions should always be made in collaboration with the patient's treating physician based on their individual clinical situation.
